Clinical trials · California
Lung Cancer (NSCLC) clinical trials in California
We’re tracking 210 recruiting lung cancer (nsclc) studies with a site in California — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT04969315RecruitingPhase 1/Phase 2
Drug TT-10 and TT-4 for advanced solid tumors
This early-phase trial tests two investigational drugs—TT-10 and TT-4—alone and together in people with advanced solid cancers. The study is designed to find safe doses and see if the treatment can shrink tumors or slow cancer growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT07100080RecruitingPhase 2/Phase 3
New drug vs chemotherapy for EGFR-mutated lung cancer
This trial tests a new drug called izalontamab brengitecan (BMS-986507) against standard chemotherapy (platinum plus pemetrexed) for people with a specific type of lung cancer that has an EGFR mutation and has stopped responding to newer targeted pills.
Irvine, CaliforniaAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT07323641RecruitingPhase 2
Telisotuzumab Vedotin and Osimertinib for Advanced Lung Cancer
This trial tests a combination of two drugs—telisotuzumab vedotin and osimertinib—for people with a specific type of advanced non-small cell lung cancer that has stopped responding to osimertinib alone. The goal is to see if adding the second drug can help control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT03526835RecruitingPhase 1/Phase 2
Study of MCLA-158 for advanced solid tumors
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
La Jolla, CaliforniaAges 18 years+ - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Newport Beach, CaliforniaAges 18 years+ - NCT05211895RecruitingPhase 3
Durvalumab plus domvanalimab after chemoradiation for stage 3 lung cancer
This trial studies whether adding durvalumab and domvanalimab after standard chemoradiation can keep unresectable stage 3 lung cancer from coming back or getting worse. It targets tumors with specific lab test results (including PD-L1 and gene markers).
Fountain Valley, CaliforniaAges 18 years+ - NCT06010329RecruitingPhase 2
Study of a new pill for advanced lung cancer with rare EGFR mutations
This trial tests an experimental pill called Sutetinib for people with advanced non-small cell lung cancer that has a rare EGFR gene change. It aims to see if the drug can shrink tumors and improve survival.
Glendale, CaliforniaAges 18 years+ - NCT05236114Recruiting
Study of blood and tumor tests for lung cancer treatment
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
Fountain Valley, CaliforniaAges 18 years+ - NCT05948865RecruitingPhase 1
Early trial drug for advanced solid tumors
This Phase 1 study tests CPO301 in adults with advanced or metastatic solid tumors that have worsened or cannot be treated with standard options. It aims to find the safest dose and understand how the treatment affects tumors, especially in certain lung cancer groups.
Santa Monica, CaliforniaAges 18 years+ - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Stanford, CaliforniaAges 18 years+ - NCT05877430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug plus pembrolizumab for advanced cancers
This Phase 1/2 study tests the safety and early signs of benefit from CJRB-101 when combined with pembrolizumab (Keytruda) in people with advanced or metastatic lung, head and neck, or melanoma cancer. It may help some participants, but the main goal is to see how safe the combination is and whether it can control cancer.
Irvine, CaliforniaAges 18 years+ - NCT06706076RecruitingPhase 1/Phase 2
Experimental pill for lung cancer with EGFR or HER2 changes
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
Irvine, CaliforniaAges 18 years+ - NCT06956690RecruitingPhase 1/Phase 2
Testing HMBD-501 for HER3-positive advanced solid tumors
This trial tests a new drug, HMBD-501, for people with advanced solid tumors that have a specific protein called HER3. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT05899608RecruitingPhase 3
Testing ivonescimab as first treatment for metastatic lung cancer
This Phase 3 trial tests ivonescimab as a first-line treatment for metastatic non-small cell lung cancer (NSCLC). It may help people by improving how well the cancer responds, especially in tumors with PD-L1 activity, but you must meet specific medical and testing requirements.
Los Angeles, CaliforniaAges 18 years+ - NCT06216301RecruitingPhase 3
Electric fields with immunotherapy and chemo for advanced lung cancer
This trial tests adding a device that delivers electric fields (Tumor Treating Fields) to standard immunotherapy and chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. It may help slow tumor growth.
Sacramento, CaliforniaAges 18 years+ - NCT02984761Recruiting
Surgery vs focused radiation for early lung cancer
This trial compares two ways to treat early-stage lung cancer: surgery or a precise type of radiation called stereotactic radiotherapy. It aims to find out which approach works best for people whose cancer is small and has not spread.
West Los Angeles, CaliforniaAges 18 years+ - NCT05652686RecruitingPhase 1/Phase 2
Studying PT217 for neuroendocrine cancers
This trial tests a new drug called Peluntamig (PT217) for people with certain types of neuroendocrine cancers, like small cell lung cancer. It aims to see if the drug can help when standard treatments stop working or aren't an option.
Duarte, CaliforniaAges 18 years+ - NCT06890598RecruitingPhase 3
Study of olomorasib for KRAS G12C-mutant lung cancer
This trial tests a new targeted therapy (olomorasib) combined with standard treatments for people with a specific type of non-small cell lung cancer that has a KRAS G12C mutation. Depending on the stage of your cancer, you may receive it before or after surgery, or along with chemotherapy and radiation.
Los Angeles, CaliforniaAges 18 years+ - NCT06868277RecruitingPhase 3
Comparing two drugs for first-line treatment of advanced lung cancer
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see which drug works better as a first treatment before any other cancer therapy.
La Mesa, CaliforniaAges 18 years+ - NCT05498428RecruitingPhase 2
Amivantamab for advanced lung cancer with EGFR mutations
This Phase 2 study tests amivantamab (an antibody medicine) in people with advanced or metastatic non-small cell lung cancer that has specific EGFR gene changes. It may help shrink tumors or control cancer when standard curative treatments aren’t possible.
Stanford, CaliforniaAges 18 years+ - NCT05830058RecruitingPhase 2
PET-guided focused radiation for limited worsening lung, melanoma, kidney cancer
This Phase 2 study tests whether using a PET scan to guide focused radiation (SBRT) can control a small number of cancer spots that are starting to grow despite prior treatment. It may help patients avoid wider radiation by targeting only the limited progressing areas.
Duarte, CaliforniaAges 18 years+ - NCT06119581RecruitingPhase 3
Oloromosib with Immunotherapy as First Treatment for KRAS G12C Lung Cancer
This trial tests a new targeted pill (olomorasib) combined with immunotherapy (pembrolizumab) and possibly chemotherapy for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and has not been treated before.
Los Angeles, CaliforniaAges 18 years+
Where these studies are running in California
Institutions with a site for the recruiting lung cancer (nsclc) studies listed above.
- University of California, Irvine Medical Center / UC Irvine Health · 4 studies
- USC / Norris Comprehensive Cancer Center · 4 studies
- City of Hope Comprehensive Cancer Center · 3 studies
- Research Site · 3 studies
- University of California San Diego Health · 3 studies
- Bass Medical Group · 2 studies
- Cedars-Sinai Medical Center · 2 studies
- Hoag Memorial Hospital Presbyterian · 2 studies
What taking part in a lung cancer (nsclc) study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Lung Cancer (NSCLC) trials in other states
Common questions
- Are there lung cancer (nsclc) clinical trials in California?
- Yes. We're currently tracking 210 recruiting lung cancer (nsclc) studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lung cancer (nsclc) study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lung cancer (nsclc) trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lung cancer (nsclc) studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.